Lilly- backed weight management biotech data IPO

.After raising $170 million back in February, metabolic disease-focused BioAge Labs has actually submitted to debut on everyone market.The Eli Lilly-partnered biotech want to note on the Nasdaq under the symbol “BIOA,” depending on to documentations filed with the Stocks as well as Exchange Percentage. The business has actually not publicly shared an assumed monetary quantity for the offering.The clinical-stage provider touts lead candidate azelaprag, an orally provided little particle slated to get into stage 2 screening in combination with semaglutide– marketed by Novo Nordisk under brand name Wegovy for fat burning– in the very first one-half of upcoming year. Semaglutide is additionally sold as Ozempic and also Rybelsus by Novo for diabetes.

Apelin receptor agonist azelaprag is actually made to combine properly along with GLP-1 medications, boosting fat loss while keeping muscle mass. The investigational drug was discovered to be well-tolerated among 265 people across eight stage 1 tests, depending on to BioAge.Earlier, BioAge achieved the assistance of Lilly to operate a test integrating azelaprag with the Large Pharma’s GLP-1/ GIP receptor agonist tirzepatide, which is actually marketed for diabetes mellitus as Mounjaro and also Zepbound for weight reduction. The companions are currently administering a phase 2 test of azelaprag and tirzepatide, along with topline outcomes anticipated in the third quarter of 2025.The biotech is also organizing an insulin sensitivity proof-of-concept test determining azelaprag as a monotherapy in the very first one-half of next year to assist prospective indicator expansion.

On top of that, the business plans to ask the FDA for approval in the second half of 2025 to launch individual testing for an NLRP3 inhibitor targeting metabolic diseases and also neuroinflammation.BioAge’s expected move to everyone market follows a light uptick in organized biotech IPOs coming from Bicara Therapies and Zenas Biopharma. Zooming out, the current IPO garden is actually a “blended image,” with high quality providers still debuting on the public markets, merely in reduced amounts, according to PitchBook.